Gregory Ciongoli
Net worth: 14 M $ as of 2026-09-29
Net worth: 14 M $ as of 2026-09-29
Mr. Gregory A. Ciongoli is an Independent Director at Gossamer Bio, Inc., an Independent Director at REGENXBIO, Inc., a Chairman at Atara Biotherapeutics, Inc. and a Managing Partner at Adiumentum Capital Management LLC.
He is on the Board of Directors at Gossamer Bio, Inc., REGENXBIO, Inc. and Zymeworks, Inc. Mr. Ciongoli was previously employed as a Partner by The Baupost Group LLC.
He received his undergraduate degree from Woodrow Wilson School of Public & International Affairs and an MBA from Harvard Business School.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ZYMEWORKS INC. 0.7% | 2026-01-11 | 493,500 ( 0.7% ) | 13 M $ | 2026-09-29 |
REGENXBIO, INC. 0.18% | 2026-08-26 | 118,035 ( 0.18% ) | 888 804 $ | 2026-09-29 |
| 2026-06-08 | 12,000 ( 0.12% ) | 102 000 $ | 2026-09-29 | |
GOSSAMER BIO, INC. -.--% | 2026-09-22 | 0 ( -.--% ) | - $ | 2026-09-29 |
| Companies | Position | Start |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Chairman | 2025-09-02 |
| ZYMEWORKS INC. | Director/Board Member | 2025-08-10 |
| REGENXBIO INC. | Director/Board Member | 2026-08-24 |
| GOSSAMER BIO, INC. | Director/Board Member | 2026-09-15 |
| Companies | Position | End |
|---|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 7 |
|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Finance |
REGENXBIO, Inc.
REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Woodrow Wilson School of Public & International Affairs
Woodrow Wilson School of Public & International Affairs Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gossamer Bio, Inc.
Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Zymeworks, Inc.
Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Select your edition
All financial news and data tailored to specific country editions